Onco360 to distribute Gilead's Zydelig
- Last week, Zydelig (idelalisib) was approved by the FDA for treatment of several types of blood cancer, including chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL).
- Onco360 will become a distributor for Zydelig, making the specialty pharmacy a part of Gilead’s very selective distribution network.
- Onco360 is focused on being a leader in the specialty oncology pharmacy market and sees Zydelig as an important addition to its portfolio.
Undoubtedly, the global oncology market is outpacing other markets and growing rapidly, with sales expected to reach $47 billion this year. Onco360 is positioning itself as a premiere pharmacy and clinical solutions company. Not only does Zydelig offer a convenient oral treatment option -- it provides a secondary treatment option for the more than 250,000 Americans who have CLL, FL or SLL.
- Pharmaceutical Business Review Onco360 named to Zydelig limited distribution network